All In Biotech

Drug Trial Radar · NCT00561951

Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo In Patients With Overactive Bladder.

Last checked: Nov 20, 2026Latest source record: Jul 14, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 951 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

951

Actual

Start

Nov 2007

Primary completion

Jan 2009

Study completion Jan 2009

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 21, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of fesoterodine in comparison to placebo for overactive bladder.

Conditions

  • Overactive Bladder

Interventions

  • fesoterodine fumarateDrug

    8mg tablets OD for 12 weeks

  • PlaceboDrug

    Corresponding placebo tablets OD for 12 weeks

  • fesoterodine fumarateDrug

    4mg tablets OD for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12.Time frame: Baseline to Week 12

Locations

65 sites in 4 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Kowloon, Hong Kong

  • Pfizer Investigational Site

    Shatin, Hong Kong

  • Pfizer Investigational Site

    Nagoya, Aichi-ken, Japan

  • Pfizer Investigational Site

    Chuo-ku, Chiba-shi, Chiba, Japan

  • Pfizer Investigational Site

    Eiheiji-cyo,yoshida-gun,, Fukui, Japan

  • Pfizer Investigational Site

    Fukuoka, Fukuoka, Japan

  • Pfizer Investigational Site

    Koga-shi, Fukuoka, Japan

  • Pfizer Investigational Site

    Minami-ku, Fukuoka-shi, Fukuoka, Japan

  • Pfizer Investigational Site

    Nishiku, Fukuoka, Japan

  • Pfizer Investigational Site

    Sawara-ku, Fukuoka, Japan

  • Pfizer Investigational Site

    Amagasaki-shi, Hyōgo, Japan

  • Pfizer Investigational Site

    Higashinada, Hyōgo, Japan

  • Pfizer Investigational Site

    Nada-ku, Kobe-shi, Hyōgo, Japan

  • Pfizer Investigational Site

    Suma-ku, Kobe-shi, Hyōgo, Japan

  • Pfizer Investigational Site

    Takaraduka-city, Hyōgo, Japan

  • Pfizer Investigational Site

    Aira-gun, Aira-chou,, Kagoshima-ken, Japan

  • Pfizer Investigational Site

    Isogo-ku, Yokohama-shi, Kanagawa, Japan

  • Pfizer Investigational Site

    Kawasakishi, Kanagawa, Japan

  • Pfizer Investigational Site

    Sagamihara-shi, Kanagawa, Japan

  • Pfizer Investigational Site

    Tama-ku, Kawasaki-shi, Kanagawa, Japan

  • Pfizer Investigational Site

    Kochi, Kochi, Japan

  • Pfizer Investigational Site

    Kumamoto, Kumamoto, Japan

  • Pfizer Investigational Site

    Tamana-shi, Kumamoto, Japan

  • Pfizer Investigational Site

    Matsumoto-shi, Nagano, Japan

  • Pfizer Investigational Site

    Matumoto-Shi, Nagano, Japan

  • Pfizer Investigational Site

    Hunaki-cho, Ibaraki-shi, Osaka, Japan

  • Pfizer Investigational Site

    Kita-ku, Osaka-shi, Osaka, Japan

  • Pfizer Investigational Site

    Kosobe-cho, Takatsuki-shi, Osaka, Japan

  • Pfizer Investigational Site

    Minami-ku, Sakai-shi, Osaka, Japan

  • Pfizer Investigational Site

    Nishinari-ku, Osaka, Japan

  • Pfizer Investigational Site

    Osaka, Osaka, Japan

  • Pfizer Investigational Site

    Suita-shi, Osaka, Japan

  • Pfizer Investigational Site

    Suita-shi,, Osaka, Japan

  • Pfizer Investigational Site

    Toyonaka, Osaka, Japan

  • Pfizer Investigational Site

    Yodogawa-Ku, Osaka, Japan

  • Pfizer Investigational Site

    Saitama-shi, Saitama, Japan

  • Pfizer Investigational Site

    Satte-shi, Saitama, Japan

  • Pfizer Investigational Site

    Wakou-shi, Saitama, Japan

  • Pfizer Investigational Site

    Gotenbashi, Shizuoka, Japan

  • Pfizer Investigational Site

    Susono, Shizuoka, Japan

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.